HGS Wastes No Time Investing In Pipeline Beyond Benlysta
One week after receiving FDA approval for its breakthrough lupus drug, Human Genome Sciences is spending $50 million for broad rights to an early-stage cancer drug that hits a popular target.
One week after receiving FDA approval for its breakthrough lupus drug, Human Genome Sciences is spending $50 million for broad rights to an early-stage cancer drug that hits a popular target.